eflornithine has been researched along with Deafness, Transitory in 6 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos." | 5.13 | Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas. ( Chen, WP; Fujikawa-Brooks, S; Gerner, EW; Gillen, DL; McLaren, CE; Meyskens, FL; Pelot, D, 2008) |
| "Recent clinical cancer chemoprevention trials, using dose de-escalation designs, indicate that DFMO can be given over long periods of time at low doses that suppress polyamine contents in gastrointestinal and other epithelial tissues but cause no detectable hearing loss or other side effects." | 2.40 | Development of difluoromethylornithine (DFMO) as a chemoprevention agent. ( Gerner, EW; Meyskens, FL, 1999) |
| "Reversible hearing loss is a recognized toxicity of DFMO that usually occurs at doses above 2 g/m(2)/d, and generally when the cumulative dose exceeds 250 g/m(2)." | 1.32 | Irreversible ototoxicity associated with difluoromethylornithine. ( Backoff, P; Brenner, DE; Eaton, T; Hawk, ET; Lao, CD; McCarty, D; Ondrey, FG; Shotland, LI; Spechler, SJ; Viner, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chow, CL | 1 |
| Havighurst, T | 1 |
| Lozar, T | 1 |
| Jones, TD | 1 |
| Kim, K | 1 |
| Bailey, HH | 1 |
| Lewis, JR | 1 |
| O'Brien, TG | 1 |
| Skorupski, KA | 1 |
| Krick, EL | 1 |
| Reiter, AM | 1 |
| Jennings, MW | 1 |
| Jurney, CH | 1 |
| Shofer, FS | 1 |
| Kim, DJ | 1 |
| Roh, E | 1 |
| Lee, MH | 1 |
| Oi, N | 1 |
| Lim, DY | 1 |
| Kim, MO | 1 |
| Cho, YY | 1 |
| Pugliese, A | 1 |
| Shim, JH | 1 |
| Chen, H | 1 |
| Cho, EJ | 1 |
| Kim, JE | 1 |
| Kang, SC | 1 |
| Paul, S | 1 |
| Kang, HE | 1 |
| Jung, JW | 1 |
| Lee, SY | 1 |
| Kim, SH | 1 |
| Reddy, K | 1 |
| Yeom, YI | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| McLaren, CE | 1 |
| Fujikawa-Brooks, S | 1 |
| Chen, WP | 1 |
| Gillen, DL | 1 |
| Pelot, D | 1 |
| Gerner, EW | 2 |
| Meyskens, FL | 2 |
| Lao, CD | 1 |
| Backoff, P | 1 |
| Shotland, LI | 1 |
| McCarty, D | 1 |
| Eaton, T | 1 |
| Ondrey, FG | 1 |
| Viner, JL | 1 |
| Spechler, SJ | 1 |
| Hawk, ET | 1 |
| Brenner, DE | 1 |
1 review available for eflornithine and Deafness, Transitory
| Article | Year |
|---|---|
Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Cell Division; Cell Trans | 1999 |
2 trials available for eflornithine and Deafness, Transitory
| Article | Year |
|---|---|
Ototoxicity of Long-Term α-Difluoromethylornithine for Skin Cancer Prevention.
Topics: Eflornithine; Hearing; Hearing Loss; Humans; Ototoxicity; Skin Neoplasms | 2023 |
Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.
Topics: Adenomatous Polyps; Antineoplastic Combined Chemotherapy Protocols; Audiometry, Pure-Tone; Colonic N | 2008 |
3 other studies available for eflornithine and Deafness, Transitory
| Article | Year |
|---|---|
Polyamine inhibitors for treatment of feline oral squamous cell carcinoma: a proof-of-concept study.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cat Diseases; Cats; Eflornithine; Evoked P | 2013 |
Herbacetin Is a Novel Allosteric Inhibitor of Ornithine Decarboxylase with Antitumor Activity.
Topics: Allosteric Regulation; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; An | 2016 |
Irreversible ototoxicity associated with difluoromethylornithine.
Topics: Antineoplastic Agents; Barrett Esophagus; Cell Proliferation; Chemoprevention; Eflornithine; Hearing | 2004 |